ViaLase is a clinical-stage medical technology company based in Aliso Viejo, CA focused on addressing unmet needs in the conventional glaucoma treatment paradigm. Its core product is the investigational ViaLase Laser, which combines femtosecond laser technology and micron-level image guidance to deliver a noninvasive procedure called femtosecond laser image-guided high-precision trabeculotomy (FLigHT). The FLigHT procedure creates channels in the trabecular meshwork to lower intraocular pressure through a noninvasive, nonsurgical approach, providing physicians with precision and visibility. The company is led by founder and CEO Tibor Juhasz, PhD. ViaLase intends to use recent financing to advance clinical, regulatory, and commercial milestones for the ViaLase Laser; the device is investigational and not approved for commercial use.

Total raised

$40M

Funding rounds

1

Latest round

Series C

Latest activity

Apr 2024